Head-to-head · WeighScore
Arc-1 vs Hims & Hers
By GLP-1 ScorecardUpdated
Score comparison
Hims & Hers has the higher recorded score — 75.6/100 to 56.3/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Arc-1 | Hims & Hers |
|---|---|---|
| WeighScore | 56.3/100 | 75.6/100 |
| Grade | C | C |
| Site position | #466 | #56 |
| Semaglutide | $199.99 starting price (0.5 mg product option; supply period unverified) | $199/mo |
| Tirzepatide | Conflicting prices ($149/mo headline; $199.99 at 2.5 mg in dose options) | Not disclosed |
| Coverage | Product exclusions differ: semaglutide AR/IN/MN/PR/SC; tirzepatide CA/AR/IN/MN/SC; individual eligibility unverified | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #466 · C
Strengths
- Terms name Arc-1 Metrics, PLLC and a Las Vegas address
- Founder Dr. Todd Stearns is named on the official site
- Semaglutide and tirzepatide product pages disclose different location exclusions
- Semaglutide advertises a $0 consultation fee and free shipping
What to consider
- Tirzepatide headline and embedded offer prices conflict
- Supply period and prescription-specific renewal/cancellation terms remain unverified
- No assigned clinician or dispensing facility established
- Generic retail return policy does not settle medication-specific refund eligibility
- Founder page uses inconsistent MD and DO labels; credentials not independently verified
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
What to consider
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.